SIMONE HOLDEN: Open Payments
NPI 1194152264 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,943 in 193 payments from 15 companies in 2025. Trend: 2023 $1,803 · 2024 $8,555 · 2025 $5,943
Food & beverage: $3,434Speaker / faculty: $2,125Consulting: $384
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 17 | $2,273 |
| ABBVIE INC. | 51 | $681 |
| Celltrion USA Inc. | 9 | $627 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 25 | $508 |
| Ardelyx, Inc. | 22 | $383 |
| Janssen Biotech, Inc. | 13 | $368 |
| GENZYME CORPORATION | 9 | $299 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $234 |
| Regeneron Healthcare Solutions, Inc. | 14 | $231 |
| Madrigal Pharmaceuticals | 4 | $77 |
Products named: VELSIPITY, DUPIXENT, XIFAXAN, ZYMFENTRA, IBSRELA, TREMFYA, RINVOQ, ENTYVIO.
Industry payments across PA — which companies pay providers there.
